• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

State of the Industry 2010: Predicted pharmaceutical spending


State of the Industry survey results

The mean forecast among survey respondents is 16.8%, much higher than Dr. Barlow's prediction. Understandably, members might estimate a high percentage, she says, because of the immediate effect they feel in their wallets when filling a prescription.

"Pharmacy is the area where you pay right out of your pocket at the time of service," she says, but adds that the real focus should be on services and procedures.

The greatest increase in pharmaceutical spending will be from specialty drugs, but that could slow down as competition in that area increases. Rising pharmaceutical spending can mean less overall healthcare spending because effective drug utilization as a first-line treatment can reduce the need for costlier, more complicated treatments later.

"The more you spend on the pharmacy sector, the better off you are in terms of medical spending," she says.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.